TY - JOUR
T1 - Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists
AU - Zhang, Xin
AU - Belousoff, Matthew J
AU - Zhao, Peishen
AU - Kooistra, Albert J
AU - Truong, Tin T
AU - Ang, Sheng Yu
AU - Underwood, Christina Rye
AU - Egebjerg, Thomas
AU - Šenel, Petr
AU - Stewart, Gregory D
AU - Liang, Yi-Lynn
AU - Glukhova, Alisa
AU - Venugopal, Hari
AU - Christopoulos, Arthur
AU - Furness, Sebastian G B
AU - Miller, Laurence J
AU - Reedtz-Runge, Steffen
AU - Langmead, Christopher J
AU - Gloriam, David E
AU - Danev, Radostin
AU - Sexton, Patrick M
AU - Wootten, Denise
N1 - Copyright © 2020 Elsevier Inc. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Peptide drugs targeting class B1 G-protein-coupled receptors (GPCRs) can treat multiple diseases; however, there remains substantial interest in the development of orally delivered non-peptide drugs. Here, we reveal unexpected overlap between signaling and regulation of the glucagon-like peptide-1 (GLP-1) receptor by the non-peptide agonist PF 06882961 and GLP-1 that was not observed for another compound, CHU-128. Compounds from these patent series, including PF 06882961, are currently in clinical trials for treatment of type 2 diabetes. High-resolution cryoelectron microscopy (cryo-EM) structures reveal that the binding sites for PF 06882961 and GLP-1 substantially overlap, whereas CHU-128 adopts a unique binding mode with a more open receptor conformation at the extracellular face. Structural differences involving extensive water-mediated hydrogen bond networks could be correlated to functional data to understand how PF 06882961, but not CHU-128, can closely mimic the pharmacological properties of GLP-1. These findings will facilitate rational structure-based discovery of non-peptide agonists targeting class B GPCRs.
AB - Peptide drugs targeting class B1 G-protein-coupled receptors (GPCRs) can treat multiple diseases; however, there remains substantial interest in the development of orally delivered non-peptide drugs. Here, we reveal unexpected overlap between signaling and regulation of the glucagon-like peptide-1 (GLP-1) receptor by the non-peptide agonist PF 06882961 and GLP-1 that was not observed for another compound, CHU-128. Compounds from these patent series, including PF 06882961, are currently in clinical trials for treatment of type 2 diabetes. High-resolution cryoelectron microscopy (cryo-EM) structures reveal that the binding sites for PF 06882961 and GLP-1 substantially overlap, whereas CHU-128 adopts a unique binding mode with a more open receptor conformation at the extracellular face. Structural differences involving extensive water-mediated hydrogen bond networks could be correlated to functional data to understand how PF 06882961, but not CHU-128, can closely mimic the pharmacological properties of GLP-1. These findings will facilitate rational structure-based discovery of non-peptide agonists targeting class B GPCRs.
U2 - 10.1016/j.molcel.2020.09.020
DO - 10.1016/j.molcel.2020.09.020
M3 - Journal article
C2 - 33027691
SN - 1097-2765
VL - 80
SP - 485
EP - 500
JO - Molecular Cell
JF - Molecular Cell
IS - 3
ER -